ConductScience.org, home

Trial · NCT04902443

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

NCT04902443, Phase 1, Recruiting, National Cancer Institute (NCI)

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV. Trials, record NCT04902443. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04902443

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
NCT number
NCT04902443
Status
Recruiting
Phases
Phase 1
Enrollment
58 participants, estimated
Lead sponsor
National Cancer Institute (NCI)
Conditions
Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
Interventions
Pomalidomide, Nivolumab
First posted
2021-05-26
Last updated
2026-10-16

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimarySafety and tolerability of pomalidomide with nivolumab24 months of treatment, until confirmed progression, unacceptable toxicity or trial withdrawalThe fraction of participants with toxicity noted at each dose level will be reported by grade and type of toxicity identified. Maximum tolerated dose will also be reported.
Secondaryanti-tumor activity and clinical benefitsEvery month (+/-1week) for 100 days after stopping treatment; then every 3 months (+/-2 weeks) for 1 year following end-of-treatment; then every 6 months
To observe and record the anti-tumor activity (RECIST 1.1, Lugano criteria or other appropriate tumor associated response criteria including modified ACTG criteria for KS) and clinical benefit in participants with Kaposi sarcoma, EBV/KSHV-associated lymphomas (evaluation of effusion-based measures), and other virus-associated malignancies treated with Pom/Nivo

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04902443

GET https://conductscience.org/api/trials/v1/NCT04902443/registered